<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="e45394bb-121f-429c-9b56-5b9c8104cfb5"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>Doxycycline Hyclate Tablets, USP</title>
   <effectiveTime value="20250426"/>
   <setId root="763997f0-b35c-43cb-a792-3e0bae589536"/>
   <versionNumber value="6"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="081468959" root="1.3.6.1.4.1.519.1"/>
            <name>Viona Pharmaceuticals Inc</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="650199482" root="1.3.6.1.4.1.519.1"/>
                  <name>Zydus Lifesciences Limited</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="863362789" root="1.3.6.1.4.1.519.1"/>
                        <name>Zydus Lifesciences Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72578-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72578-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="00883222-f6eb-4049-b27b-8c8b6c7ecd9d"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20250426"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="72578-001" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Doxycycline Hyclate</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Doxycycline Hyclate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="100" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="19XTS3T51U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DOXYCYCLINE HYCLATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="334895S862" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DOXYCYCLINE ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS LACTOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="50" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="72578-001-18" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20190314"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="72578-001-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20190314"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="72578-001-05" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20190314"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1000" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="72578-001-10" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20190314"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="72578-001-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="72578-001-77" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20190314"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA207773" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190314"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW">
                              <originalText>beige colored</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND">
                              <originalText>biconvex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" value="9" unit="mm"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">D77</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID1">
               <id root="744bdff1-06b4-4cc0-8336-dc241e921415"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph ID="ID2">To reduce the development of drug-resistant   bacteria and maintain   the effectiveness of Doxycycline and other antibacterial drugs, Doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.</paragraph>
               </text>
               <effectiveTime value="20190314"/>
            </section>
         </component>
         <component>
            <section ID="ID3">
               <id root="8ffae230-0174-46db-9eeb-3b6b66a259d0"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph ID="ID4">Doxycycline hyclate is an antibacterial drug synthetically derived from oxytetracycline. The chemical designation for doxycycline is 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacene-carboxamide  monohydrate.</paragraph>
                  <paragraph>Doxycycline hyclate is yellow to light yellow powder. It is freely soluble in water and methanol, sparingly soluble in alcohol; practically insoluble in chloroform and in ether. It dissolves in aqueous solution of alkali hydroxides and carbonates.</paragraph>
                  <paragraph>Doxycycline has a high degree of lipoid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxycycline will not degrade into an epianhydro form. The structural formula is as follows:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph ID="ID6">Each film-coated tablet for oral administration contains doxycycline hyclate equivalent to 100 mg of doxycycline (anhydrous).  Inactive ingredients are: anhydrous lactose, croscarmellose sodium, colloidal silicon dioxide, hypromellose, iron oxide yellow , iron oxide red, microcrystalline cellulose, magnesium stearate, polyethylene glycol, pregelatinised starch and titanium dioxide.</paragraph>
               </text>
               <effectiveTime value="20250426"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Doxycycline hyclate tablets</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="e45394bb-121f-429c-9b56-5b9c8104cfb5-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID7">
               <id root="e0522f22-ccec-4243-9152-7280d8d7484d"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph ID="ID8">Tetracyclines are readily absorbed and are bound to plasma proteins in varying degree. They are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations and in a biologically active form. Doxycycline is virtually completely absorbed after oral administration.</paragraph>
                  <paragraph>Following a 200 mg dose, normal adult volunteers averaged peak serum levels of 2.6 mcg/mL of doxycycline at 2 hours, decreasing to 1.45 mcg/mL at 24 hours. Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with normal function (creatinine clearance about 75 mL/min). This percentage excretion may fall as low as 1 to 5%/72 hours in individuals with severe renal insufficiency (creatinine clearance below 10 mL/min). Studies have shown no significant difference in serum half-life of doxycycline (range 18 to 22 hours) in individuals with normal and severely impaired renal function. </paragraph>
                  <paragraph>Hemodialysis does not alter serum half-life.</paragraph>
                  <paragraph>Results of animal studies indicate that tetracyclines cross the placenta and are found in fetal tissues.</paragraph>
                  <paragraph>Population pharmacokinetic analysis of sparse concentration-time data of doxycycline following standard of care intravenous and oral dosing in 44 pediatric patients (2 years to 18 years of age) showed that allometrically-scaled clearance (CL) of doxycycline in pediatric patients ≥2 to ≤8 years of age (median [range] 3.58 [2.27 to 10.82] L/h/70 kg, N =11) did not differ significantly from pediatric patients &gt;8 to 18 years of age (3.27 [1.11 to 8.12] L/h/70 kg, N=33). For pediatric patients weighing ≤45 kg, body weight normalized doxycycline CL in those ≥2 to ≤8 years of age (median [range] 0.071 [0 .041 to 0.202] L/kg/h, N=10) did not differ significantly from those &gt;8 to 18 years of age (0.081 [0.035 to 0.126] L/kg/h, N=8). In pediatric patients weighing &gt;45 kg, no clinically significant differences in body weight normalized doxycycline CL were observed between those ≥2 to ≤8 years (0.050 L/kg/h, N=l) and those &gt;8 to 18 years of age (0.044 [0.014 to 0.121] L/kg/h, N=25). No clinically significant difference in CL between oral and IV dosing was observed in the small cohort of pediatric patients who received the oral (N=19) or IV (N=2l) formulation alone.</paragraph>
               </text>
               <effectiveTime value="20241227"/>
               <component>
                  <section ID="ID9">
                     <id root="7c7f8dbe-98e9-4248-8d3b-e990f6f485de"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>Microbiology</title>
                     <text>
                        <paragraph ID="ID10">
                           <content styleCode="bold">
                              <content styleCode="italics">Mechanism of Action</content>
                           </content>
                        </paragraph>
                        <paragraph>Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. </paragraph>
                        <paragraph>Doxycycline has bacteriostatic activity against a broad range of Gram-positive and Gram-negative bacteria. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Resistance</content>
                           </content>
                        </paragraph>
                        <paragraph>Cross resistance with other tetracyclines is common. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Antimicrobial Activity</content>
                           </content>
                        </paragraph>
                        <paragraph>Doxycycline has been shown to be active against most isolates of the following microorganisms, both <content styleCode="italics">in vitro </content>and in clinical infections as described in the <content styleCode="bold">INDICATIONS AND USAGE</content> section of the package insert for doxycycline hyclate tablets.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID11">
                     <id root="4dfb5da0-000a-4a9d-9944-1a559130af20"/>
                     <title>Gram-Negative Bacteria</title>
                     <text>
                        <paragraph ID="ID12">
                           <content styleCode="italics">Acinetobacter </content>species </paragraph>
                        <paragraph>
                           <content styleCode="italics">Bartonella bacilliformis </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Brucella </content>species </paragraph>
                        <paragraph>
                           <content styleCode="italics">Klebsiella </content>species </paragraph>
                        <paragraph>
                           <content styleCode="italics">Klebsiella granulomatis </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Campylobacter fetus </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Enterobacter aerogenes </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Escherichia coli </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Francisella tularensis </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Haemophilus ducreyi </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Haemophilus influenzae </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Neisseria gonorrhoeae </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Shigella </content>species </paragraph>
                        <paragraph>
                           <content styleCode="italics">Vibrio cholerae </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Yersinia pestis</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20190314"/>
                  </section>
               </component>
               <component>
                  <section ID="ID13">
                     <id root="7f82af8b-948e-4dcc-afda-e6e133bdded3"/>
                     <title>Gram-Positive Bacteria</title>
                     <text>
                        <paragraph ID="ID14">
                           <content styleCode="italics">Bacillus anthracis </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Listeria monocytogenes</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Streptococcus pneumoniae</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20190314"/>
                  </section>
               </component>
               <component>
                  <section ID="ID15">
                     <id root="82a873fe-9592-4f33-a061-77102a218d01"/>
                     <title>Anaerobic Bacteria</title>
                     <text>
                        <paragraph ID="ID16">
                           <content styleCode="italics">Clostridium </content>species </paragraph>
                        <paragraph>
                           <content styleCode="italics">Fusobacterium fusiforme </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Propionibacterium acnes</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20190314"/>
                  </section>
               </component>
               <component>
                  <section ID="ID96">
                     <id root="1a771756-b9a1-4008-92c8-a8f0f9c4231e"/>
                     <title>Other Bacteria</title>
                     <text>
                        <paragraph ID="ID97">
                           <content styleCode="italics">Nocardiae </content>and other aerobic <content styleCode="italics">Actinomyces </content>species </paragraph>
                        <paragraph>
                           <content styleCode="italics">Borrelia recurrentis </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Chlamydophila psittaci </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Chlamydia trachomatis </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Mycoplasma pneumoniae </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Rickettsiae </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Treponema pallidum </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Treponema pallidum </content>subspecies <content styleCode="italics">pertenue </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Ureaplasma urealyticum</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20190314"/>
                  </section>
               </component>
               <component>
                  <section ID="ID98">
                     <id root="66e791a1-020a-4891-8826-08e847c403db"/>
                     <title>Parasites</title>
                     <text>
                        <paragraph ID="ID99">
                           <content styleCode="italics">Balantidium coli </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Entamoeba </content>species </paragraph>
                        <paragraph>
                           <content styleCode="italics">Plasmodium falciparum<sup>*</sup>
                           </content>
                        </paragraph>
                        <paragraph>
                           <sup>*</sup>Doxycycline has been found to be active against the asexual erythrocytic forms of <content styleCode="italics">Plasmodium falciparum</content>, but not against the gametocytes of <content styleCode="italics">P. falciparum</content>. The precise mechanism of action of the drug is not known.</paragraph>
                     </text>
                     <effectiveTime value="20190314"/>
                  </section>
               </component>
               <component>
                  <section ID="ID17">
                     <id root="9b9c0e42-f17e-4718-8acc-55836bd6ef8e"/>
                     <title>Susceptibility Testing</title>
                     <text>
                        <paragraph ID="ID18">For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.</paragraph>
                     </text>
                     <effectiveTime value="20200416"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID26">
               <id root="97d78533-532c-46c8-91e8-804de60173f1"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph ID="ID27">To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate tablets and other antibacterial drugs, doxycycline hyclate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.   In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
               </text>
               <effectiveTime value="20250408"/>
               <component>
                  <section ID="ID28">
                     <id root="9b003282-cbe6-4a6e-a26a-b3378b3499d1"/>
                     <title>Treatment</title>
                     <text>
                        <paragraph ID="ID95">Doxycycline hyclate tablets are indicated for the treatment of the following infections:</paragraph>
                        <list listType="unordered" ID="ID30" styleCode="Disc">
                           <item>  Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by <content styleCode="italics">Rickettsiae</content> .</item>
                           <item>  Respiratory tract infections caused by <content styleCode="italics">Mycoplasma pneumoniae</content> .</item>
                           <item>  Lymphogranuloma venereum caused by <content styleCode="italics">Chlamydia trachomatis</content> .</item>
                           <item>  Psittacosis (ornithosis) caused by <content styleCode="italics">Chlamydophila </content>
                              <content styleCode="italics"> psittaci</content> .</item>
                           <item>  Trachoma caused by <content styleCode="italics">Chlamydia trachomatis</content> , although the infectious agent is not always eliminated, as judged by immunofluorescence.</item>
                           <item>  Inclusion conjunctivitis caused by <content styleCode="italics">Chlamydia trachomatis</content> .</item>
                           <item>  Uncomplicated urethral, endocervical, or rectal infections in adults caused by <content styleCode="italics">Chlamydia trachomatis</content> .</item>
                           <item>  Nongonococcal urethritis caused by <content styleCode="italics">Ureaplasma urealyticum</content> .</item>
                           <item>  Relapsing fever due to <content styleCode="italics">Borrelia recurrentis</content> .</item>
                        </list>
                        <paragraph ID="ID31">Doxycycline hyclate tablets are also indicated for the treatment of infections caused by the following gram-negative microorganisms:</paragraph>
                        <list listType="unordered" ID="ID32" styleCode="Disc">
                           <item>Chancroid caused by <content styleCode="italics">Haemophilus ducreyi</content>.</item>
                           <item>Plague due to <content styleCode="italics">Yersinia pestis</content>.</item>
                           <item>Tularemia due to <content styleCode="italics">Francisella tularensis.</content>
                           </item>
                           <item>Cholera caused by <content styleCode="italics">Vibrio cholerae.</content>
                           </item>
                           <item>Campylobacter fetus infections caused by <content styleCode="italics">Campylobacter fetus</content>.</item>
                           <item>Brucellosis due to <content styleCode="italics">Brucella </content>species (in conjunction with streptomycin).</item>
                           <item>Bartonellosis due to <content styleCode="italics">Bartonella bacilliformis.</content>
                           </item>
                           <item>Granuloma inguinale caused by <content styleCode="italics">Klebsiella granulomatis.</content>
                           </item>
                        </list>
                        <paragraph ID="ID33">Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended.</paragraph>
                        <paragraph>Doxycycline hyclate tablets are indicated for treatment of infections caused by the following gram-negative bacteria, when bacteriologic testing indicates appropriate susceptibility to the drug:</paragraph>
                        <list listType="unordered" ID="ID34" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Escherichia coli.</content>
                           </item>
                           <item>
                              <content styleCode="italics">Enterobacter aerogenes</content> .</item>
                           <item>
                              <content styleCode="italics">Shigella </content> species<content styleCode="italics">.</content>
                           </item>
                           <item>
                              <content styleCode="italics">Acinetobacter </content> species.</item>
                           <item>Respiratory tract infections caused by <content styleCode="italics">Haemophilus influenzae</content> .</item>
                           <item>Respiratory tract and urinary tract infections caused by <content styleCode="italics">Klebsiella</content> species.</item>
                        </list>
                        <paragraph ID="ID35">Doxycycline hyclate tablets are indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:</paragraph>
                        <list listType="unordered" ID="ID36" styleCode="Disc">
                           <item>Upper respiratory infections caused by <content styleCode="italics">Streptococcus pneumoniae</content> .</item>
                           <item>Anthrax due to <content styleCode="italics">Bacillus anthracis</content> , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized <content styleCode="italics">Bacillus anthracis</content> .</item>
                        </list>
                        <paragraph ID="ID37">When penicillin is contraindicated, doxycycline hyclate tablets are an alternative drug in the treatment of the following infections:</paragraph>
                        <list listType="unordered" ID="ID38" styleCode="Disc">
                           <item>Uncomplicated      gonorrhea caused by <content styleCode="italics">Neisseria gonorrhoeae</content> .</item>
                           <item>Syphilis      caused by <content styleCode="italics">Treponema pallidum.</content>
                           </item>
                           <item>Yaws caused by <content styleCode="italics">Treponema pallidum</content> subspecies<content styleCode="italics">pertenue</content> .</item>
                           <item>Listeriosis      due to <content styleCode="italics">Listeria monocytogenes</content> .</item>
                           <item>Vincent's      infection caused by <content styleCode="italics">Fusobacterium fusiforme</content> .</item>
                           <item>Actinomycosis      caused by <content styleCode="italics">Actinomyces israelii</content> .</item>
                           <item>Infections      caused by <content styleCode="italics">Clostridium</content> species.</item>
                        </list>
                        <paragraph ID="ID39">In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. </paragraph>
                        <paragraph>In severe acne, doxycycline may be useful adjunctive therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250408"/>
                  </section>
               </component>
               <component>
                  <section ID="ID40">
                     <id root="3257c689-8798-4db9-944d-2c99403656c1"/>
                     <title>Prophylaxis</title>
                     <text>
                        <paragraph ID="ID41">Doxycycline hyclate tablets are indicated for the prophylaxis of malaria due to <content styleCode="italics">Plasmodium falciparum</content> in short- term travelers (&lt;4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains.  (<content styleCode="italics">See <content styleCode="bold">
                                 <linkHtml href="#ID78">DOSAGE AND ADMINISTRATION</linkHtml>
                              </content> section </content>and<content styleCode="italics"> <content styleCode="bold">
                                 <linkHtml href="#ID48">Information for Patients </linkHtml>
                              </content>subsection of the <content styleCode="bold">PRECAUTIONS</content> section)</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID42">
               <id root="6aea09b3-98b8-40cd-823e-85706529e2a7"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="ID43">This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.</paragraph>
               </text>
               <effectiveTime value="20190314"/>
            </section>
         </component>
         <component>
            <section ID="ID44">
               <id root="88250604-3de8-4764-bf01-eb60432385ee"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph ID="ID45">The use of drugs of the tetracycline class during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of the drugs, but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. Use doxycycline in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g., anthrax, Rocky Mountain spotted fever), particularly when there are no alternative therapies.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Clostridioides difficile</content> associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Doxycycline, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <content styleCode="italics">C. difficile</content>.</paragraph>
                  <paragraph>
                     <content styleCode="italics">C. difficile</content> produces toxins A and B which contribute to the development of CDAD.  Hypertoxin producing strains of <content styleCode="italics">C. difficile</content> cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea following the use of antibacterial drugs.  Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</paragraph>
                  <paragraph>If CDAD is suspected or confirmed, ongoing use of antibacterial drugs not directed against <content styleCode="italics">C. difficile</content> may need to be discontinued.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of <content styleCode="italics">C. difficile</content>, and surgical evaluation should be instituted as clinically indicated. </paragraph>
                  <paragraph>Severe skin reactions, such as exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in patients receiving doxycycline. Fixed drug eruptions have occurred with doxycycline and have been associated with worsening severity upon subsequent administrations, including generalized bullous fixed drug eruption (<content styleCode="italics">See</content> <content styleCode="bold">
                        <content styleCode="italics">ADVERSE REACTIONS.</content>
                     </content>) If severe skin reactions occur, discontinue doxycycline hyclate tablets immediately and institute appropriate therapy.</paragraph>
                  <paragraph>Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracyclines including Doxycycline. Clinical manifestations of IH include headache, blurred vision, diplopia, and vision loss; papilledema can be found on fundoscopy. Women of childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline associated IH. Concomitant use of isotretinoin and Doxycycline should be avoided because isotretinoin is also known to cause pseudotumor cerebri. </paragraph>
                  <paragraph>Although IH typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. If visual disturbance occurs during treatment, prompt ophthalmologic evaluation is warranted. Since intracranial pressure can remain elevated for weeks after drug cessation patients should be monitored until they stabilize.</paragraph>
                  <paragraph>All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate has been observed in prematures given oral tetracycline in doses of 25 mg/kg every 6 hours. This reaction was shown to be reversible when the drug was discontinued. </paragraph>
                  <paragraph>Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity has also been noted in animals treated early in pregnancy. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. </paragraph>
                  <paragraph>The antianabolic action of the tetracyclines may cause an increase in BUN. Studies to date indicate that this does not occur with the use of doxycycline in patients with impaired renal function. </paragraph>
                  <paragraph>Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.</paragraph>
               </text>
               <effectiveTime value="20250408"/>
            </section>
         </component>
         <component>
            <section ID="ID46">
               <id root="7acbee0a-8fea-41b4-a7e4-69f7482335b5"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <text>
                  <paragraph ID="ID47">
                     <content styleCode="bold">General</content>
                  </paragraph>
                  <paragraph>As with other antibacterial drugs, use of Doxycycline may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, Doxycycline should be discontinued and appropriate therapy instituted.</paragraph>
                  <paragraph>Incision and drainage or other surgical procedures should be performed in conjunction with antibacterial therapy, when indicated.</paragraph>
                  <paragraph>Doxycycline offers substantial but not complete suppression of the asexual blood stages of Plasmodium strains.</paragraph>
                  <paragraph>Doxycycline does not suppress <content styleCode="italics">P. falciparum's</content> sexual blood stage gametocytes.  Subjects completing this prophylactic regimen may still transmit the infection to mosquitoes outside endemic areas.</paragraph>
                  <paragraph>Prescribing Doxycycline in the absence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</paragraph>
               </text>
               <effectiveTime value="20190314"/>
            </section>
         </component>
         <component>
            <section ID="ID48">
               <id root="36fd6fd5-597d-4e90-aef3-f794fa452309"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>Information For Patients</title>
               <text>
                  <paragraph ID="ID49">Patients taking doxycycline for malaria prophylaxis should be advised:</paragraph>
                  <list listType="unordered" ID="ID51" styleCode="Disc">
                     <item>that no present-day antimalarial agent, including doxycycline, guarantees protection against malaria.</item>
                     <item>to avoid being bitten by mosquitoes by using personal protective measures that help avoid contact with mosquitoes, especially from dusk to dawn (e.g., staying in well-screened areas, using mosquito nets, covering the body with clothing, and using an effective insect repellent).</item>
                     <item>that doxycycline prophylaxis:</item>
                     <item>should begin 1 to 2 days before travel to the malarious area,</item>
                     <item>should be continued daily while in the malarious area and after leaving the malarious area,</item>
                     <item>should be continued for 4 further weeks to avoid development of malaria after returning from an endemic area,</item>
                     <item>should not exceed 4 months.</item>
                  </list>
                  <paragraph ID="ID52">All patients taking doxycycline should be advised:</paragraph>
                  <list listType="unordered" ID="ID53" styleCode="Disc">
                     <item>  to avoid excessive sunlight or artificial ultraviolet light while receiving doxycycline and to discontinue therapy if phototoxicity (e.g., skin eruption, etc.) occurs. Sunscreen or sunblock should be considered. (<content styleCode="italics">See <content styleCode="bold">
                              <linkHtml href="#ID44">WARNINGS</linkHtml>
                           </content>
                        </content>
                        <content styleCode="bold">)</content> .</item>
                     <item>  to drink fluids liberally along with doxycycline to reduce the risk of esophageal irritation and ulceration. (<content styleCode="italics">See <content styleCode="bold">
                              <linkHtml href="#ID71">ADVERSE REACTIONS</linkHtml>).</content>
                        </content>
                     </item>
                     <item>  that the absorption of tetracyclines is reduced when taken with foods, especially those which contain calcium. However, the absorption of doxycycline is not markedly influenced by simultaneous ingestion of food or milk. (<content styleCode="italics">See <content styleCode="bold">
                              <linkHtml href="#ID57">DRUG INTERACTIONS</linkHtml>
                           </content>
                        </content> .)</item>
                     <item>  that the absorption of tetracyclines is reduced when taking bismuth subsalicylate (<content styleCode="italics">See<content styleCode="bold">
                              <linkHtml href="#ID57">DRUG INTERACTIONS</linkHtml>
                           </content>
                        </content> .)</item>
                     <item>  that the use of doxycycline might increase the incidence of vaginal candidiasis.</item>
                  </list>
                  <paragraph ID="ID54">Patients should be counseled that antibacterial drugs, including doxycycline hyclate should only be used to treat bacterial infections.  They do not treat viral infections (e.g., the common cold). When doxycycline hyclate tablets are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed.  Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by doxycycline or other antibacterial drugs in the future.</paragraph>
                  <paragraph>Diarrhea is a common problem caused by antibacterial drugs, which usually ends when the antibacterials are discontinued.  Sometimes after starting treatment with antibacterial drugs, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterial drug.  If this occurs, patients should contact their physician as soon as possible.</paragraph>
               </text>
               <effectiveTime value="20241227"/>
               <component>
                  <section ID="ID55">
                     <id root="0bc02cb1-e0a4-4114-92b1-6df8aeab5caa"/>
                     <code code="34075-2" codeSystem="2.16.840.1.113883.6.1" displayName="LABORATORY TESTS SECTION"/>
                     <title>Laboratory Tests</title>
                     <text>
                        <paragraph ID="ID56">In venereal disease, when co existent syphilis is suspected, dark field examinations should be done before treatment is started and the blood serology repeated monthly for at least 4 months. In long-term therapy, periodic laboratory evaluation of organ systems, including hematopoietic, renal, and hepatic studies, should be performed.</paragraph>
                     </text>
                     <effectiveTime value="20190314"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID57">
               <id root="8a52a015-aad8-4adc-84a4-a9747d983ab3"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>Drug Interactions</title>
               <text>
                  <paragraph ID="ID58">Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.</paragraph>
                  <paragraph>Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.</paragraph>
                  <paragraph>Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.</paragraph>
                  <paragraph>Absorption of tetracyclines is impaired by bismuth subsalicylate.</paragraph>
                  <paragraph>Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.</paragraph>
                  <paragraph>Concurrent use of tetracycline may render oral contraceptives less effective.</paragraph>
               </text>
               <effectiveTime value="20250408"/>
               <component>
                  <section ID="ID59">
                     <id root="051d4d17-5ce6-492b-8dc3-e678a0a5b719"/>
                     <title>Drug/Laboratory Test Interactions</title>
                     <text>
                        <paragraph ID="ID60">False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.</paragraph>
                     </text>
                     <effectiveTime value="20190314"/>
                  </section>
               </component>
               <component>
                  <section ID="ID61">
                     <id root="4648c1ab-0a1f-4c7b-9606-a23ccb971905"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment Of Fertility</title>
                     <text>
                        <paragraph ID="ID62">Long-term studies in animals to evaluate carcinogenic potential of doxycycline have not been conducted.  However, there has been evidence of oncogenic activity in rats in studies with the related antibacterial drugs, oxytetracycline (adrenal and pituitary tumors), and minocycline (thyroid tumors).</paragraph>
                        <paragraph>Likewise, although mutagenicity studies of doxycycline have not been conducted, positive results in <content styleCode="italics">in</content> <content styleCode="italics">vitro</content> mammalian cell assays have been reported for related antibacterial drugs (tetracycline, oxytetracycline).</paragraph>
                        <paragraph>Doxycycline administered orally at dosage levels as high as 250 mg/kg/day had no apparent effect on the fertility of female rats.  Effect on male fertility has not been studied.</paragraph>
                     </text>
                     <effectiveTime value="20200413"/>
                  </section>
               </component>
               <component>
                  <section ID="ID63">
                     <id root="377d1c46-2d58-4c24-aef9-97f08030f787"/>
                     <title>Pregnancy: Teratogenic Effects.</title>
                     <text>
                        <paragraph ID="ID64">There are no adequate and well-controlled studies on the use of doxycycline in pregnant women.  The vast majority of reported experience with doxycycline during human pregnancy is short-term, first trimester exposure.  There are no human data available to assess the effects of long-term therapy of doxycycline in pregnant women, such as that proposed for treatment of anthrax exposure. An expert review of published data on experiences with doxycycline use during pregnancy by TERIS – the Teratogen Information System – concluded that therapeutic doses during pregnancy are unlikely to pose a substantial  teratogenic  risk (the quantity and quality of data were assessed as limited to fair), but the data are insufficient  to state that there is no risk.<sup>1</sup> A case-control study (18,515 mothers of infants with congenital anomalies and 32,804 mothers of infants with no congenital anomalies) shows a weak but marginally statistically significant association with total malformations and use of doxycycline anytime during pregnancy. Sixty-three (0.19%) of the controls and fifty-six (0.30%) of the cases were treated with doxycycline. This association was not seen when the analysis was confined to maternal treatment during the period of organogenesis (i.e., in the second and third months of gestation) with the exception of a marginal relationship with neural tube defect based on only two exposed cases.<sup>2</sup>
                        </paragraph>
                        <paragraph>A small prospective study of 81 pregnancies describes 43 pregnant women treated for 10 days with doxycycline during early first trimester.  All mothers reported their exposed infants were normal at 1 year of age.<sup>3</sup>
                        </paragraph>
                        <paragraph>Nonteratogenic Effects: (<content styleCode="italics">See <content styleCode="bold">
                                 <linkHtml href="#ID44">WARNINGS</linkHtml>
                              </content>
                           </content>).</paragraph>
                     </text>
                     <effectiveTime value="20190314"/>
                  </section>
               </component>
               <component>
                  <section ID="ID65">
                     <id root="76f5b715-59b1-432a-b262-b40c317259e9"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>Labor and Delivery</title>
                     <text>
                        <paragraph ID="ID66">The effect of tetracyclines on labor and delivery is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20190314"/>
                  </section>
               </component>
               <component>
                  <section ID="ID67">
                     <id root="7b2868b7-e43a-48e6-97af-0e6423a1cd4e"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph ID="ID68">Tetracyclines are excreted in human milk; however, the extent of absorption of tetracyclines, including doxycycline, by the breastfed infant is not known. Short-term use by lactating women is not necessarily contraindicated; however, the effects of prolonged exposure to doxycycline in breast milk are unknown.<sup>4</sup> Because of the potential for serious adverse reactions in nursing infants from doxycycline, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. (<content styleCode="italics">See <content styleCode="bold">
                                 <linkHtml href="#ID44">WARNINGS</linkHtml>
                              </content>
                           </content>.)</paragraph>
                     </text>
                     <effectiveTime value="20200413"/>
                  </section>
               </component>
               <component>
                  <section ID="ID69">
                     <id root="92881bdd-217c-4955-9cd1-6805b6b04f7e"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph ID="ID70">Because of the effects of drugs of the tetracycline-class on tooth development and growth, use doxycycline in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g., anthrax, Rocky Mountain spotted fever), particularly when there are no alternative therapies. (See <content styleCode="bold">
                              <content styleCode="italics">
                                 <linkHtml href="#ID44">WARNINGS</linkHtml> </content>
                           </content>and <content styleCode="bold">
                              <content styleCode="italics">
                                 <linkHtml href="#ID78">DOSAGE AND ADMINISTRATION</linkHtml>
                              </content>
                           </content>.)</paragraph>
                     </text>
                     <effectiveTime value="20200413"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID71">
               <id root="5fdac6b6-1e1d-4481-a05b-d93cd4bb7b1f"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="ID72">Due to oral doxycycline's virtually   complete absorption, side effects of the lower bowel, particularly diarrhea, have been infrequent.  The following adverse reactions   have been observed in patients receiving tetracyclines:</paragraph>
               </text>
               <effectiveTime value="20241227"/>
               <component>
                  <section ID="ID100">
                     <id root="91e4803a-7020-413f-a483-3b9b0dac5f76"/>
                     <title>Gastrointestinal:</title>
                     <text>
                        <paragraph ID="ID101">anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, inflammatory lesions (with monilial overgrowth) in the anogenital region and pancreatitis. Hepatotoxicity has been reported rarely. These reactions have been caused by both the oral and parenteral administration of tetracyclines. Superficial discoloration of the adult permanent dentition, reversible upon drug discontinuation and professional dental cleaning has been reported. Permanent tooth discoloration and enamel hypoplasia may occur with drugs of the tetracycline class when used during tooth development. (<content styleCode="italics">See <content styleCode="bold">
                                 <linkHtml href="#ID44">WARNINGS</linkHtml>.</content>
                           </content>) Rare instances of esophagitis and esophageal ulcerations have been reported in patients receiving capsule and tablet forms of the drugs in the tetracycline class. Most of these patients took medications immediately before going to bed. (<content styleCode="italics">See<content styleCode="bold"> <linkHtml href="#ID78">DOSAGE AND ADMINISTRATION</linkHtml>)</content>
                           </content>.</paragraph>
                     </text>
                     <effectiveTime value="20200413"/>
                  </section>
               </component>
               <component>
                  <section ID="ID73">
                     <id root="b2ff4968-829d-4389-ac9e-16e833a82cde"/>
                     <title>Skin</title>
                     <text>
                        <paragraph ID="ID91">toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, fixed drug eruption, skin hyperpigmentation, maculopapular and erythematous rashes. Exfoliative dermatitis has been reported but is uncommon. Photosensitivity is discussed above. (<content styleCode="italics">See <content styleCode="bold">
                                 <linkHtml href="#ID44">WARNINGS</linkHtml>
                              </content>
                           </content>.)</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID74">
                     <id root="490a5efc-65b9-4cfb-850e-92e75ec0cb27"/>
                     <title>Renal toxicity:</title>
                     <text>
                        <paragraph ID="ID75">Rise in BUN has been reported and is apparently dose related. (<content styleCode="italics">See <content styleCode="bold">
                                 <linkHtml href="#ID44">WARNINGS</linkHtml>
                              </content>
                           </content>
                           <content styleCode="bold">)</content>. </paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID102">
                     <id root="0fb69665-f708-4570-bdc5-9284ad258e05"/>
                     <title>Immune:</title>
                     <text>
                        <paragraph ID="ID103">Hypersensitivity reactions including urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness, pericarditis, exacerbation of systemic lupus erythematosus, drug reaction with eosinophilia and systemic symptoms (DRESS) and Jarisch-Herxheimer reaction has been reported in the setting of spirochete infections treated with doxycycline.</paragraph>
                     </text>
                     <effectiveTime value="20200413"/>
                  </section>
               </component>
               <component>
                  <section ID="ID104">
                     <id root="729b32ef-a168-45f2-888a-65177782fe95"/>
                     <title>Blood:</title>
                     <text>
                        <paragraph ID="ID105">Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported. </paragraph>
                     </text>
                     <effectiveTime value="20190314"/>
                  </section>
               </component>
               <component>
                  <section ID="ID108">
                     <id root="db8af478-48ea-49f1-820a-9dbf8acad7d1"/>
                     <title>Psychiatric:</title>
                     <text>
                        <paragraph ID="ID109">Depression, anxiety, suicidal ideation, insomnia, abnormal dreams, hallucination</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID106">
                     <id root="20e62287-753b-475d-96e6-ecae5d91e48d"/>
                     <title>Other:</title>
                     <text>
                        <paragraph ID="ID107">Bulging fontanels in infants and intracranial hypertension in adults. (<content styleCode="italics">See  <content styleCode="bold">
                                 <linkHtml href="#ID44">WARNINGS</linkHtml>
                              </content>).</content>
                        </paragraph>
                        <paragraph>When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of the thyroid gland. No abnormalities of thyroid function studies are known to occur.</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Viona Pharmaceuticals Inc. at 1-888-304-5011 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID76">
               <id root="e7e43e1a-403f-47e5-9b7a-1f0cc06d33bd"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph ID="ID77">In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Dialysis does not alter serum half-life and thus would not be of benefit in treating cases of overdosage.</paragraph>
               </text>
               <effectiveTime value="20190314"/>
            </section>
         </component>
         <component>
            <section ID="ID78">
               <id root="5689394e-05c2-4739-a805-e2e2a42d40b4"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph ID="ID79">The usual dosage and frequency of administration of doxycycline differs from that of the other tetracyclines. Exceeding the recommended dosage may result in an increased incidence of side effects.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Adults</content>
                  </paragraph>
                  <paragraph>The usual dose of oral doxycycline is 200 mg on the first day of treatment (administered 100 mg every 12 hours) followed by a maintenance dose of 100 mg/day. In the management of more severe infections (particularly chronic infections of the urinary tract), 100 mg every 12 hours is recommended.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Pediatric Patients</content>
                  </paragraph>
                  <paragraph>For all pediatric patients weighing less than 45 kg with severe or life-threatening infections (e.g., anthrax, Rocky Mountain spotted fever), the recommended dosage is 2.2 mg/kg of body weight administered every 12 hours. Children weighing 45 kg or more should receive the adult dose. (See <content styleCode="bold">
                        <content styleCode="italics">
                           <linkHtml href="#ID44">WARNINGS</linkHtml>
                        </content>
                     </content> <content styleCode="bold">
                        <content styleCode="italics">AND <linkHtml href="#ID46">PRECAUTIONS</linkHtml>
                        </content>
                     </content>). </paragraph>
                  <paragraph>For pediatric patients with less severe disease (greater than 8 years of age and weighing less than 45 kg), the recommended dosage schedule is 4.4 mg/kg of body weight divided into two doses on the first day of treatment, followed by a maintenance dose of 2.2 mg/kg of body weight (given as a single daily dose or divided into twice daily doses). For pediatric patients weighing over 45 kg, the usual adult dose should be used. </paragraph>
                  <paragraph>The therapeutic antibacterial serum activity will usually persist for 24 hours following recommended dosage.</paragraph>
                  <paragraph>When used in streptococcal infections, therapy should be continued for 10 days. </paragraph>
                  <paragraph>Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. (<content styleCode="italics">See <content styleCode="bold">
                           <linkHtml href="#ID71">ADVERSE REACTIONS</linkHtml>
                        </content>
                     </content>).</paragraph>
                  <paragraph>If gastric irritation occurs, it is recommended that doxycycline be given with food or milk. The absorption of doxycycline is not markedly influenced by simultaneous ingestion of food or milk. </paragraph>
                  <paragraph>Studies to date have indicated that administration   of doxycycline at the usual recommended doses does not lead to excessive accumulation of doxycycline in patients with renal impairment. </paragraph>
                  <paragraph>Uncomplicated gonococcal infections in adults (except anorectal infections in men): 100 mg, by mouth, twice a day for 7 days. As an alternate single visit dose, administer 300 mg stat followed in one hour by a second 300 mg dose. The dose may be administered with food, including milk or carbonated beverage, as required.</paragraph>
                  <paragraph>Uncomplicated urethral, endocervical, or rectal infection in adults caused by <content styleCode="italics">Chlamydia</content> <content styleCode="italics">trachomatis</content>: 100 mg, by mouth twice a day for 7 days.</paragraph>
                  <paragraph>Nongonococcal urethritis (NGU) caused by <content styleCode="italics">C. trachomatis</content> or <content styleCode="italics">U. urealyticum</content>: 100 mg by mouth, twice a day for 7 days.</paragraph>
                  <paragraph>Syphilis - early: Patients who are allergic to penicillin should be treated with doxycycline 100 mg by mouth, twice a day for 2 weeks.</paragraph>
                  <paragraph>Syphilis of more than one year's duration:  Patients who are allergic to penicillin should be treated with doxycycline 100 mg by mouth, twice a day for 4 weeks.</paragraph>
                  <paragraph>Acute epididymo-orchitis   caused by <content styleCode="italics">N. gonorrhoeae</content>: 100 mg by mouth, twice a day for at least 10 days.</paragraph>
                  <paragraph>Acute epididymo-orchitis   caused by <content styleCode="italics">C. trachomatis</content>:  100 mg by mouth, twice a day for at least 10 days.</paragraph>
                  <paragraph>For prophylaxis   of malaria:  For adults, the recommended dose is 100 mg daily. For children over 8 years of age, the recommended dose is 2 mg/kg given once daily up to the adult dose. Prophylaxis should begin 1 to 2 days before travel to the malarious area. Prophylaxis should be continued daily during travel in the malarious area and for 4 weeks after the traveler leaves the malarious area.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Inhalational anthrax (post-exposure)</content>
                  </paragraph>
                  <paragraph>ADULTS: 100 mg of doxycycline, by mouth, twice a day for 60 days.</paragraph>
                  <paragraph>CHILDREN: weighing less than 45 kg; 2.2 mg/kg of body weight, by mouth, twice a day for 60 days. Children weighing 45 kg or more should receive the adult dose.</paragraph>
               </text>
               <effectiveTime value="20200416"/>
            </section>
         </component>
         <component>
            <section ID="ID80">
               <id root="8bef3d45-b7e3-48e4-ad2d-1358333ee75a"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph ID="ID81">Each film-coated tablet for oral administration contains doxycycline hyclate equivalent to 100 mg of doxycycline (anhydrous).</paragraph>
                  <paragraph>Doxycycline hyclate tablets USP, equivalent to 100 mg doxycycline: Light yellow to beige colored, round, beveled edge, biconvex tablets debossed with "D77" on one side and plain on other side.  </paragraph>
                  <paragraph>NDC 72578-001-18 in bottle of 50 tablets with child-resistant closure</paragraph>
                  <paragraph>NDC 72578-001-01 in bottle of 100 tablets</paragraph>
                  <paragraph>NDC 72578-001-05 in bottle of 500 tablets</paragraph>
                  <paragraph>NDC 72578-001-10 in bottle of 1000 tablets</paragraph>
                  <paragraph>NDC 72578-001-77 in cartons of 100 tablets (10 x 10 unit-dose)</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage:</content>
                  </paragraph>
                  <paragraph>Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature]. Protect from light and moisture.</paragraph>
                  <paragraph>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</paragraph>
               </text>
               <effectiveTime value="20250408"/>
            </section>
         </component>
         <component>
            <section ID="ID89">
               <id root="40c8a2fb-b192-4678-874d-246053715841"/>
               <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
               <title>ANIMAL PHARMACOLOGY AND ANIMAL TOXICOLOGY</title>
               <text>
                  <paragraph ID="ID90">Hyperpigmentation of the thyroid has been produced by members of the tetracycline class in the following species: in rats by oxytetracycline, doxycycline, tetracycline PO<sub> 4</sub> and methacycline; in minipigs by doxycycline, minocycline, tetracycline PO<sub> 4</sub>, and methacycline; in dogs by doxycycline and minocycline; in monkeys by minocycline.</paragraph>
                  <paragraph>Minocycline, tetracycline PO<sub>4</sub>, methacycline, doxycycline, tetracycline base, oxytetracycline hydrochloride, and tetracycline hydrochloride were goitrogenic in rats fed a low iodine diet. This goitrogenic effect was accompanied by high radioactive iodine uptake. Administration of minocycline also produced a large goiter with high radioiodine uptake in rats fed a relatively high iodine diet. Treatment of various animal species with this class of drugs has also resulted in the induction of thyroid hyperplasia in the following: in rats and dogs (minocycline); in chickens (chlortetracycline); and in rats and mice (oxytetracycline).  Adrenal gland hyperplasia has been observed in goats and rats treated with oxytetracycline. </paragraph>
               </text>
               <effectiveTime value="20200416"/>
            </section>
         </component>
         <component>
            <section ID="ID82">
               <id root="3119bab3-e84d-47e8-a065-793aee39994e"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>REFERENCES</title>
               <text>
                  <list listType="ordered" ID="ID93">
                     <item>Friedman JM and Polifka JE. <content styleCode="italics">Teratogenic Effects of Drugs. A Resource for Clinicians (TERIS)</content>. Baltimore, MD: The Johns Hopkins University Press, 2000: 149–195.</item>
                     <item>Cziezel AE and Rockenbauer M. Teratogenic study of doxycycline. <content styleCode="italics">Obstet Gynecol</content> 1997; 89: 524–528.</item>
                     <item>Horne HW Jr and Kundsin RB. The role of mycoplasma among 81 consecutive pregnancies: a prospective study. <content styleCode="italics">Int J Fertil</content> 1980; 25: 315–317.</item>
                     <item>Hale T. <content styleCode="italics">Medications and Mothers Milk</content>. 9<sup>th</sup> edition. Amarillo, TX: Pharmasoft Publishing, 2000: 225-226.</item>
                  </list>
                  <paragraph ID="ID83">
                     <content styleCode="bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250408"/>
            </section>
         </component>
         <component>
            <section ID="ID84">
               <id root="83e34bc4-dcff-4ef5-b51e-d3b432c80749"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph ID="ID85">
                     <content styleCode="bold">Manufactured by:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Zydus Lifesciences Ltd.</content>
                  </paragraph>
                  <paragraph>Ahmedabad, India.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Distributed by:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Viona Pharmaceuticals Inc.</content>
                  </paragraph>
                  <paragraph>Cranford, NJ 07016</paragraph>
                  <paragraph>Rev.: 04/25</paragraph>
               </text>
               <effectiveTime value="20250408"/>
            </section>
         </component>
         <component>
            <section ID="ID86">
               <id root="3fcac842-c252-4dbf-a633-fd44fa29eea6"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph ID="ID87">NDC 72578-001-18</paragraph>
                  <paragraph>Doxycycline hyclate tablets, 100 mg</paragraph>
                  <paragraph>50 tablets</paragraph>
                  <paragraph>Rx only</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20250426"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Doxycycline hyclate tablets</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="e45394bb-121f-429c-9b56-5b9c8104cfb5-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>